Taltz 80 mg solution for injection in pre-filled syringe

DRUG5 trials

Sponsors

Azienda Ospedaliera Ordine Mauriziano Di Torino, University Of Gothenburg, NU Hospital Group-Vaestra Goetalandsregionen, Universitair Ziekenhuis Gent, Rigshospitalet, University Hospital Of Ferrara

Conditions

Axial SpondyloarthritisDiabetes type 1PSORIATIC ARTHRITISPsoriatic Arthritismoderate-to-severe psoriasispsoriatic arthritis (PsA)

Phase 2

A randomized placebo controlled clinical trial of preserving endogenous insulin production with Ixekizumab in newly diagnosed persons with type 1 diabetes

Active, not recruitingCTIS2023-508588-58-00

University Of Gothenburg, NU Hospital Group-Vaestra GoetalandsregionenDiabetes type 1

Start: 2022-10-25Target: 127Updated: 2025-11-26

Phase 3

Clinical and ultrasound assessment of the therapeutic response to ixekizumab in psoriatic arthritis dactlylitis; a multicentre, parallel-groups, randomised controlled trial

Not yet recruitingCTIS2022-503119-40-00

Azienda Ospedaliera Ordine Mauriziano Di Torinopsoriatic arthritis (PsA)

Target: 60Updated: 2025-04-23

Phase 4

Detailed assessment of axial and peripheral entheses and joints in axial spondyloarthritis and psoriatic arthritis patients treated with ixekizumab – a 2-year study applying whole-body MRI, MRI-based synthetic CT, and CT

RecruitingCTIS2024-510746-14-00

RigshospitaletAxial Spondyloarthritis, Psoriatic Arthritis

Start: 2024-08-28Target: 65Updated: 2024-04-05

Proactive therapeutic drug monitoring versus routine care with the novel biologics in psoriasis: a pragmatic, multicentric, randomised, controlled study (HELIOS)

RecruitingCTIS2023-509637-39-00

Universitair Ziekenhuis Gentmoderate-to-severe psoriasis

Start: 2024-11-28Target: 210Updated: 2026-01-08

IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY.

Not yet recruitingCTIS2025-521259-21-00

University Hospital Of FerraraPSORIATIC ARTHRITIS

Target: 30Updated: 2025-06-24